Other
CAR-T
0
Pipeline Programs↗
7
Active Trials↗
1
Companies Involved↗
CAR-T is an early-stage landscape with 0 programs across 1 company. The most active players are Chengdu Ucello Biotechnology Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
9
clinical trials
Recruiting4 · 44%
Not yet recruiting2 · 22%
Unknown status1 · 11%
Active, not recruiting1 · 11%
Suspended1 · 11%
Clinical Trials
Trial Activity
9 trials
CAR-T Followed by Bispecific Antibodies
Recruiting·—·Phase 2·NCT04889716·42 enrolled
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
Active, not recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06220097·28 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)